|
1
|
Cheifetz S, Andres JL and Massagué J: The
transforming growth factor-beta receptor type III is a membrane
proteoglycan. Domain structure of the receptor. J Biol Chem.
263:16984–16991. 1988.PubMed/NCBI
|
|
2
|
Hempel N, How T, Dong M, Murphy SK, Fields
TA and Blobe GC: Loss of betaglycan expression in ovarian cancer:
Role in motility and invasion. Cancer Res. 67:5231–5238. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang XF, Lin HY, Ng-Eaton E, Downward J,
Lodish HF and Weinberg RA: Expression cloning and characterization
of the TGF-beta type III receptor. Cell. 67:797–805. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
López-Casillas F, Cheifetz S, Doody J,
Andres JL, Lane WS and Massagué J: Structure and expression of the
membrane proteoglycan betaglycan, a component of the TGF-beta
receptor system. Cell. 67:785–795. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morén A, Ichijo H and Miyazono K:
Molecular cloning and characterization of the human and porcine
transforming growth factor-beta type III receptors. Biochem Biophys
Res Commun. 189:356–362. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gatza CE, Oh SY and Blobe GC: Roles for
the type III TGF-beta receptor in human cancer. Cell Signal.
22:1163–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
López-Casillas F, Payne HM, Andres JL and
Massagué J: Betaglycan can act as a dual modulator of TGF-beta
access to signaling receptors: Mapping of ligand binding and GAG
attachment sites. J Cell Biol. 124:557–568. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Esparza-Lopez J, Montiel JL,
Vilchis-Landeros MM, Okadome T, Miyazono K and López-Casillas F:
Ligand binding and functional properties of betaglycan, a
co-receptor of the transforming growth factor-beta superfamily.
Specialized binding regions for transforming growth factor-beta and
inhibin A. J Biol Chem. 276:14588–14596. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kirkbride KC, Ray BN and Blobe GC:
Cell-surface co-receptors: Emerging roles in signaling and human
disease. Trends Biochem Sci. 30:611–621. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bernabeu C, Lopez-Novoa JM and Quintanilla
M: The emerging role of TGF-beta superfamily coreceptors in cancer.
Biochim Biophys Acta. 1792:954–973. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bilandzic M and Stenvers KL: Betaglycan: A
multifunctional accessory. Mol Cell Endocrinol. 339:180–189. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Andres JL, Stanley K, Cheifetz S and
Massagué J: Membrane-anchored and soluble forms of betaglycan, a
polymorphic proteoglycan that binds transforming growth
factor-beta. J Cell Biol. 109:3137–3145. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bandyopadhyay A, Zhu Y, Cibull ML, Bao L,
Chen C and Sun L: A soluble transforming growth factor β type III
receptor suppresses tumorigenicity and metastasis of human breast
cancer MDA-MB-231 cells. Cancer Res. 59:5041–5046. 1999.PubMed/NCBI
|
|
14
|
Cheung HK, Mei J and Xu RJ: Quantification
of soluble beta-glycan in porcine milk. Asia Pac J Clin Nutr.
12:S612003.
|
|
15
|
Velasco-Loyden G, Arribas J and
López-Casillas F: The shedding of betaglycan is regulated by
pervanadate and mediated by membrane type matrix metalloprotease-1.
J Biol Chem. 279:7721–7733. 2004. View Article : Google Scholar
|
|
16
|
Bandyopadhyay A, Wang L, López-Casillas F,
Mendoza V, Yeh IT and Sun L: Systemic administration of a soluble
beta-glycan suppresses tumor growth, angiogenesis, and matrix
metalloproteinase-9 expression in a human xenograft model of
prostate cancer. Prostate. 63:81–90. 2005. View Article : Google Scholar
|
|
17
|
Juárez P, Vilchis-Landeros MM, Ponce-Coria
J, Mendoza V, Hernández-Pando R, Bobadilla NA and López-Casillas F:
Soluble betaglycan reduces renal damage progression in db/db mice.
Am J Physiol Renal Physiol. 292:F321–F329. 2007. View Article : Google Scholar
|
|
18
|
Yan Z, Deng X and Friedman E: Oncogenic
Ki-ras confers a more aggressive colon cancer phenotype through
modification of transforming growth factor-beta receptor III. J
Biol Chem. 276:1555–1563. 2001. View Article : Google Scholar
|
|
19
|
Mythreye K and Blobe GC: The type III
TGF-beta receptor regulates epithelial and cancer cell migration
through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad
Sci USA. 106:8221–8226. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Eickelberg O, Centrella M, Reiss M,
Kashgarian M and Wells RG: Betaglycan inhibits TGF-beta signaling
by preventing type I-type II receptor complex formation.
Glycosaminoglycan modifications alter betaglycan function. J Biol
Chem. 277:823–829. 2002. View Article : Google Scholar
|
|
21
|
Gordon KJ, Dong M, Chislock EM, Fields TA
and Blobe GC: Loss of type III transforming growth factor beta
receptor expression increases motility and invasiveness associated
with epithelial to mesenchymal transition during pancreatic cancer
progression. Carcinogenesis. 29:252–262. 2008. View Article : Google Scholar
|
|
22
|
Antony ML, Nair R, Sebastian P and
Karunagaran D: Changes in expression, and/or mutations in TGF-β
receptors (TGF-β RI and TGF-β RII) and Smad 4 in human ovarian
tumors. J Cancer Res Clin Oncol. 136:351–361. 2010. View Article : Google Scholar
|
|
23
|
Liu XL, Xiao K, Xue B, Yang D, Lei Z, Shan
Y and Zhang HT: Dual role of TGFBR3 in bladder cancer. Oncol Rep.
30:130–138. 2013.
|
|
24
|
Zakrzewski PK, Mokrosiński J, Cygankiewicz
AI, Semczuk A, Rechberger T, Skomra D and Krajewska WM:
Dysregulation of betaglycan expression in primary human endometrial
carcinomas. Cancer Invest. 29:137–144. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Semczuk A, Zakrzewski PK, Forma E,
Cygankiewicz AI, Semczuk-Sikora A, Bryś M, Rechberger T and
Krajewska WM: TGFβ-pathway is down-regulated in a uterine
carcinosarcoma: A case study. Pathol Res Pract. 209:740–744. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
28
|
Cawkwell L, Bell SM, Lewis FA, Dixon MF,
Taylor GR and Quirke P: Rapid detection of allele loss in
colorectal tumours using microsatellites and fluorescent DNA
technology. Br J Cancer. 67:1262–1267. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Didkowska J, Wojciechowska U and Zatoński
W: Cancer in Poland in 2011. National M. Sklodowska-Curie Cancer
Center; Warsaw: pp. 13–21. 2001
|
|
30
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Drabsch Y and ten Dijke P: TGF-β
signalling and its role in cancer progression and metastasis.
Cancer Metastasis Rev. 31:553–568. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Principe DR, Doll JA, Bauer J, Jung B,
Munshi HG, Bartholin L, Pasche B, Lee C and Grippo PJ: TGF-β:
Duality of function between tumor prevention and carcinogenesis. J
Natl Cancer Inst. 106:djt3692014. View Article : Google Scholar
|
|
33
|
Blobe GC, Schiemann WP, Pepin MC,
Beauchemin M, Moustakas A, Lodish HF and O'Connor-McCourt MD:
Functional roles for the cytoplasmic domain of the type III
transforming growth factor β receptor in regulating transforming
growth factor β signaling. J Biol Chem. 276:24627–24637. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Guo X and Wang XF: Signaling cross-talk
between TGF-β/BMP and other pathways. Cell Res. 19:71–88. 2009.
View Article : Google Scholar
|
|
35
|
Zhang YE: Non-Smad pathways in TGF-β
signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar :
|
|
36
|
Hanks BA, Holtzhausen A, Evans KS,
Jamieson R, Gimpel P, Campbell OM, Hector-Greene M, Sun L, Tewari
A, George A, et al: Type III TGF-β receptor downregulation
generates an immunotolerant tumor microenvironment. J Clin Invest.
123:3925–3940. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
37
|
Copland JA, Luxon BA, Ajani L, Maity T,
Campagnaro E, Guo H, LeGrand SN, Tamboli P and Wood CG: Genomic
profiling identifies alterations in TGFbeta signaling through loss
of TGFbeta receptor expression in human renal cell carcinogenesis
and progression. Oncogene. 22:8053–8062. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong M, How T, Kirkbride KC, Gordon KJ,
Lee JD, Hempel N, Kelly P, Moeller BJ, Marks JR and Blobe GC: The
type III TGF-beta receptor suppresses breast cancer progression. J
Clin Invest. 117:206–217. 2007. View
Article : Google Scholar
|
|
39
|
Hempel N, How T, Cooper SJ, Green TR, Dong
M, Copland JA, Wood CG and Blobe GC: Expression of the type III
TGF-beta receptor is negatively regulated by TGF-beta.
Carcinogenesis. 29:905–912. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sharifi N, Hurt EM, Kawasaki BT and Farrar
WL: TGFBR3 loss and consequences in prostate cancer. Prostate.
67:301–311. 2007. View Article : Google Scholar
|
|
41
|
Turley RS, Finger EC, Hempel N, How T,
Fields TA and Blobe GC: The type III transforming growth
factor-beta receptor as a novel tumor suppressor gene in prostate
cancer. Cancer Res. 67:1090–1098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Finger EC, Turley RS, Dong M, How T,
Fields TA and Blobe GC: TbetaRIII suppresses non-small cell lung
cancer invasiveness and tumorigenicity. Carcinogenesis. 29:528–535.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gordon KJ and Blobe GC: Role of
transforming growth factor-beta superfamily signaling pathways in
human disease. Biochim Biophys Acta. 1782:197–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bae HJ, Eun JW, Noh JH, Kim JK, Jung KH,
Xie HJ, Park WS, Lee JY and Nam SW: Downregulation of transforming
growth factor β receptor type III in hepatocellular carcinoma is
not directly associated with genetic alterations or loss of
heterozygosity. Oncol Rep. 22:475–480. 2009.PubMed/NCBI
|
|
45
|
Bilandzic M, Chu S, Farnworth PG, Harrison
C, Nicholls P, Wang Y, Escalona RM, Fuller PJ, Findlay JK and
Stenvers KL: Loss of betaglycan contributes to the malignant
properties of human granulosa tumor cells. Mol Endocrinol.
23:539–548. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu XL, Xue BX, Lei Z, Yang DR, Zhang QC,
Shan YX and Zhang HT: TGFBR3 co-downregulated with GATA3 is
associated with methylation of the GATA3 gene in bladder urothelial
carcinoma. Anat Rec (Hoboken). 296:1717–1723. 2013. View Article : Google Scholar
|
|
47
|
Ragnarsson G, Eiriksdottir G,
Johannsdottir JT, Jonasson JG, Egilsson V and Ingvarsson S: Loss of
heterozygosity at chromosome 1p in different solid human tumours:
Association with survival. Br J Cancer. 79:1468–1474. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Florio P, Ciarmela P, Reis FM, Toti P,
Galleri L, Santopietro R, Tiso E, Tosi P and Petraglia F: Inhibin
α-subunit and the inhibin coreceptor betaglycan are downregulated
in endometrial carcinoma. Eur J Endocrinol. 152:277–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Cooper SJ, Zou H, Legrand SN, Marlow LA,
von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW,
et al: Loss of type III transforming growth factor-beta receptor
expression is due to methylation silencing of the transcription
factor GATA3 in renal cell carcinoma. Oncogene. 29:2905–2915. 2010.
View Article : Google Scholar : PubMed/NCBI
|
